Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

Edgewise Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma sector. The company focuses on Biotechnology and has secured $32.3B in funding across 60 round(s). With a team of 51-100 employees, Edgewise Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Edgewise Therapeutics, raised $240.0M. Discover more about their projects, partnerships, and impact on our platform.